NYSEAMERICAN:SER

Serina Therapeutics Q3 2026 Earnings Results & Report

Serina Therapeutics logo
$1.36 -0.06 (-3.87%)
Closing price 04:10 PM Eastern
Extended Trading
$1.36 0.00 (-0.07%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Serina Therapeutics reported Q3 2026 earnings on November 12, 2026. The company reported EPS of -$0.31, while revenue was $130 thousand.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call
7:00 AM ET

Serina Therapeutics EPS Results

Actual EPS
-$0.31
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Serina Therapeutics Revenue Results

Actual Revenue
$130 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Serina Therapeutics Q3 2026 Earnings FAQ

Serina Therapeutics (NYSEAMERICAN:SER) reported earnings of -$0.31 per share for Q3 2026. The report was announced on Thursday, November 12, 2026.

Serina Therapeutics reported revenue of $130 thousand for Q3 2026.

Serina Therapeutics Earnings Headlines

Serina Therapeutics (NYSEAMERICAN:SER) Stock Price Up 2.2% - Still a Buy?
Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
See More Serina Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Serina Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Serina Therapeutics and other key companies, straight to your email.

About Serina Therapeutics

Serina Therapeutics (NYSEAMERICAN:SER) is a clinical-stage biotechnology company developing medicines using its proprietary POZ polymer drug-delivery platform. The technology is designed to attach to therapeutic molecules and potentially improve their delivery, dosing characteristics, or tolerability.

Its lead program, SER-252, combines the POZ polymer with apomorphine and is being developed for people with advanced Parkinson’s disease. The company’s broader platform may be applied to small-molecule drugs, peptides, and other therapeutic compounds.

Serina became publicly traded following a 2024 business combination with AgeX Therapeutics. The company is based in the United States.

View Serina Therapeutics Profile